MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 10, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from multiple

MONROVIA, Calif. --(BUSINESS WIRE)--Jun. 22, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced the presentation of new preclinical data from three XmAb ® 2+1

-- Engineered IL2-Fc Cytokine is Well-tolerated and Selectively Expands Regulatory T Cells -- PASADENA, Calif. --(BUSINESS WIRE)--May 30, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with

MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 3, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced updated clinical data from a Phase 1 study of

(BW Healthwire)–May 29, 2002—Xencor’s Protein Design Technology Provides Superior Control and Flexibility in Biotherapeutic Creation

Xencor Licenses Xtend ™ Therapeutic Protein Half-life Extension Technology to CSL MONROVIA, Calif., and MELBOURNE, Australia, April 16, 2013—Xencor, Inc. announced today that Xencor and CSL Limited have entered into a technology license agreement to provide CSL access to Xencor's Xtend™

Xencor Licenses Xtend ™ Antibody Half-life Prolongation Platform to Merck & Co., Inc. Monrovia, CA – March 23, 2009 – Xencor, Inc., an antibody discovery and development company, announced today that is has entered into a licensing transaction with Merck & Co., Inc.

Xencor Licenses Protein Variants to Lilly Monrovia, CA – April 13, 2005 – Xencor today announced that Eli Lilly and Company has exercised its option to develop one or more therapeutic proteins created by Xencor under its collaboration with Lilly. Xencor used its proprietary Protein Design

(BW Healthwire)–March 11, 2002—Xencor President and CEO Presents at SG Cowen Health Care Conference Today at 10:00 am EST

Xencor Licenses Immunofilter™ Technology to Centocor Research and Development, Inc. Monrovia, CA – February 14, 2006 – Xencor, Inc., a biotherapeutics company developing protein and antibody therapeutics, today announced that it has granted Centocor Research and Development, Inc.